Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Star Bulk Carriers Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Star Bulk Carriers Corp trades at $27.91 (market cap $3.09B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.6× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SBLK | |
|---|---|---|
Market Cap | $29.60B | $3.09B |
Sector | Health | Industrials |
52-Week High | $491.22 | $29.15 |
52-Week Low | $205.48 | $16.79 |
Enterprise Value | $27.56B | $3.77B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Star Bulk Carriers (SBLK) trades at $27.89, down 1.86% on the day, amid a bullish technical signal and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Valuation metrics appear attractive with a P/E of 10.85 and EV/EBITDA of 7.46, while profitability improved significantly with a net margin of 23.87% in 2026. Recent news highlights dividend declarations and strong operational results.
Outlook remains positive driven by earnings beats and healthy cash flow, though risks include dry bulk rate volatility and competitive pressures. Analyst consensus is bullish with 14 buy ratings, supporting potential upside, but investors should monitor shipping market cycles and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
